This Drug Discovery TechVision Opportunity Engine (TOE) provides insights across research advances in gene editing technologies that have enabled enhanced drug screening and target discovery. Furthermore, the service also includes regulatory advances for 3,4-methlyenedioxymethamaphetamine and Ibrutinib therapies. Interestingly, the TOE encompasses advances in novel target discovery for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD). Lastly, the TOE summarizes key technologies and trends fueling the growing use of Big Data for drug discovery applications.
The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.
The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: Gene editing, CRISPR, drug discovery, drug screening, cancer immunotherapy, immune checkpoint inhibitor, lentivirus transduction, synthetic lethality, posttraumatic stress disorder, MDMA, chronic graft-versus-host-disease, Imbruvica, tyrosine kinase inhibitor, neurodegenerative diseases, Alzheimer’s disease, amyotrophic lateral sclerosis, Big Data, predictive analytics, artificial intelligence, cloud computing